Compare PLETHICO PHARMA with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ALKEM LABORATORIES PLETHICO PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x -1.1 - - View Chart
P/BV x 0.0 6.4 0.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PLETHICO PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ALKEM LABORATORIES
Mar-16
PLETHICO PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3951,589 24.9%   
Low Rs311,232 2.5%   
Sales per share (Unadj.) Rs604.4417.5 144.8%  
Earnings per share (Unadj.) Rs32.556.3 57.7%  
Cash flow per share (Unadj.) Rs51.364.7 79.3%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs473.6292.9 161.7%  
Shares outstanding (eoy) m34.08119.57 28.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.4 10.4%   
Avg P/E ratio x6.625.1 26.2%  
P/CF ratio (eoy) x4.221.8 19.0%  
Price / Book Value ratio x0.54.8 9.3%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m7,262168,653 4.3%   
No. of employees `000NANA-   
Total wages/salary Rs m1,5969,171 17.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,59849,915 41.3%  
Other income Rs m3861,645 23.5%   
Total revenues Rs m20,98451,561 40.7%   
Gross profit Rs m2,8188,482 33.2%  
Depreciation Rs m6421,006 63.9%   
Interest Rs m1,593671 237.6%   
Profit before tax Rs m9698,451 11.5%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,606 -8.6%   
Profit after tax Rs m1,1076,731 16.4%  
Gross profit margin %13.717.0 80.5%  
Effective tax rate %-14.319.0 -75.2%   
Net profit margin %5.413.5 39.8%  
BALANCE SHEET DATA
Current assets Rs m18,87727,062 69.8%   
Current liabilities Rs m11,89615,324 77.6%   
Net working cap to sales %33.923.5 144.1%  
Current ratio x1.61.8 89.9%  
Inventory Days Days3667 54.0%  
Debtors Days Days19841 479.2%  
Net fixed assets Rs m9,86112,610 78.2%   
Share capital Rs m341239 142.5%   
"Free" reserves Rs m12,33134,490 35.8%   
Net worth Rs m16,13935,027 46.1%   
Long term debt Rs m4,7061,212 388.4%   
Total assets Rs m33,14654,387 60.9%  
Interest coverage x1.613.6 11.8%   
Debt to equity ratio x0.30 843.0%  
Sales to assets ratio x0.60.9 67.7%   
Return on assets %8.113.6 59.9%  
Return on equity %6.919.2 35.7%  
Return on capital %12.324.9 49.4%  
Exports to sales %21.412.9 165.1%   
Imports to sales %15.23.1 493.4%   
Exports (fob) Rs m4,4026,461 68.1%   
Imports (cif) Rs m3,1361,540 203.6%   
Fx inflow Rs m4,4026,563 67.1%   
Fx outflow Rs m3,1843,012 105.7%   
Net fx Rs m1,2193,552 34.3%   
CASH FLOW
From Operations Rs m2,4377,259 33.6%  
From Investments Rs m-6,2651,864 -336.1%  
From Financial Activity Rs m2,490-9,273 -26.9%  
Net Cashflow Rs m-1,337-150 891.4%  

Share Holding

Indian Promoters % 82.7 66.9 123.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 33.1 13.0%  
FIIs % 5.5 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 0.0 -  
Shareholders   10,665 68,381 15.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - NOVARTIS COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS